Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
Sawada, Takahiro; Shinke, Toshiro; Shite, Junya; Honjo, Tomoyuki; Haraguchi, Yoko; Nishio, Ryo; Shinohara, Masakazu; Toh, Ryuji; Ishida, Tatsuro; Kawamori, Hiroyuki; Kozuki, Amane; Inoue, Takumi; Hariki, Hirotoshi; Hirata, Ken-ichi.
; 75(1): 99-105, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21099121
A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Frequency and risk of noncardiac surgery after drug-eluting stent implantation.
Coronary stenting with the Genous™ Bio-Engineered R Stent™ in elderly patients.
Failure of high-dose clopidogrel in recurrent stent thrombosis.
Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials.
Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents.
Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.